Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe.

Abstract

BACKGROUND:

A randomised, blinded, positive controlled, multicentre, Good Clinical Practice-compliant, pivotal field study was conducted to evaluate the effectiveness and safety of a new combination of lotilaner + milbemycin oxime tablets (Credelio® Plus; Elanco Animal Health) administered orally to client-owned dogs naturally infected with intestinal nematodes.

METHODS:

Client-owned dogs presenting to veterinary clinics from households in France, Hungary and Germany were screened for intestinal nematodes. Dogs with an initial positive faecal egg count that was subsequently confirmed with a follow-up faecal examination to demonstrate the presence of naturally occurring mixed or mono-infections with Toxocara canis, Toxascaris leonina, Trichuris vulpis or Ancylostoma caninum were enrolled on Day 0 into the study. Households were randomised in an approximately 2:1 ratio to receive either an investigational product (IP; Credelio Plus tablets) or control product (CP; Nexgard Spectra® tablets) as treatment. Dogs were administered the IP (n = 278) or CP (n = 117) once on Day 0 at a dose rate of 0.75-1.56 mg/kg bodyweight milbemycin oxime and 20.0-41.5 mg/kg bodyweight lotilaner (IP) or as recommended (CP). Effectiveness of the IP and CP treatments was based on the post-treatment reduction in geometric mean faecal egg counts on Day 8 (range Day 7-10) after treatment as compared to their pre-treatment nematode faecal egg counts.

RESULTS:

Geometric mean (GM) faecal egg counts for T. canis, A caninum and T. vulpis were reduced by ≥ 97.2% in the Credelio Plus group and  by ≥ 95.3% in the afoxolaner + milbemycin oxime group. There were insufficient data to calculate a percentage reduction in GM faecal egg counts between Day 0 and Day 8 for T. leonina due to low prevalence. Credelio Plus was well tolerated in this field study. Of the 355 total doses administered, 82.3% were accepted free choice in the IP group compared to 80.8% in the CP group.

CONCLUSIONS:

This study demonstrated effectiveness (≥ 97.2% reduction), safety and tablet acceptance of a combination of milbemycin oxime and lotilaner (Credelio Plus) administered orally to dogs with natural intestinal infections of T. canis, A. caninum and T. vulpis.

• Authors: Brad Hayes, Scott Wiseman, Daniel E Snyder
• Journal: Parasites & vectors (Parasit Vectors) Vol. 14 Issue 1 Pg. 258 (May 17 2021) ISSN: 1756-3305 [Electronic] England
• PMID: 34001223 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Drug Combinations
• Macrolides
• Oxazoles
• Thiophenes
• lotilaner
• milbemycin oxime

Topics

• Animals
• Dog Diseases (drug therapy, parasitology)
• Dogs
• Drug Combinations
• Europe (epidemiology)
• Feces (parasitology)
• Female
• Hospitals, Animal (statistics & numerical data)
• Macrolides (standards, therapeutic use)
• Male
• Nematoda (classification, drug effects)
• Nematode Infections (drug therapy, epidemiology)
• Oxazoles (standards, therapeutic use)
• Parasite Egg Count
• Parasitic Diseases, Animal (drug therapy, epidemiology)
• Pets (parasitology)
• Random Allocation
• Thiophenes (standards, therapeutic use)